Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)179.28m
- Net income in EUR34.01m
- Incorporated1986
- Employees500.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Yizhong Pharmaceutical Co Ltd | 30.13m | 2.80m | 1.34bn | 65.00 | 471.02 | 7.54 | -- | 44.60 | 0.1132 | 0.1132 | 1.22 | 7.07 | 0.163 | 0.9556 | 2.26 | 3,800,801.00 | 1.51 | 5.44 | 1.58 | 5.64 | 81.39 | 92.99 | 9.30 | 36.90 | 7.84 | -- | 0.00 | 32.30 | -51.83 | -- | -95.68 | -- | 10.96 | -- |
| Jubilant Pharmova Ltd | 736.77m | 40.26m | 1.35bn | 978.00 | 33.53 | -- | 17.04 | 1.83 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Biotest AG | 635.20m | -24.50m | 1.36bn | 2.50k | -- | 2.86 | -- | 2.14 | -0.6505 | -0.6505 | 16.37 | 12.88 | 0.4437 | 1.01 | 2.88 | 254,589.20 | -1.72 | 0.4411 | -2.13 | 0.5137 | 23.19 | 28.69 | -3.87 | 0.9225 | 1.66 | 0.268 | 0.5675 | 13.41 | 6.08 | 11.62 | -79.21 | -- | -3.39 | -- |
| Veradermics Inc | 0.00 | -45.34m | 1.37bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| Cansino Biologics Inc | 118.52m | -17.32m | 1.37bn | 1.11k | -- | 2.99 | -- | 11.55 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 802.21m | 83.91m | 1.37bn | 8.26k | 16.62 | 1.58 | -- | 1.71 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
| Natco Pharma Ltd | 424.30m | 144.89m | 1.37bn | 4.20k | 9.48 | -- | 8.20 | 3.24 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Immunocore Holdings PLC - ADR | 319.83m | -24.62m | 1.37bn | 493.00 | -- | -- | -- | 4.30 | -0.5866 | -0.5866 | 7.49 | -- | 0.3471 | 0.5336 | 5.44 | 769,959.40 | -2.67 | -17.90 | -3.34 | -23.26 | 99.29 | -- | -7.70 | -53.74 | 5.97 | -- | 0.4975 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Guangzhou Innogen Pharmaceutl Grp Co Ltd | -10.78bn | -10.78bn | 1.38bn | 105.00 | -- | 15.00 | -- | -- | -- | -- | -- | 1.84 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.39 | -- | 0.0769 | -- | -- | -- | 76.18 | -- | -- | -- |
| Vimian Group AB | 424.15m | 31.13m | 1.38bn | 1.20k | 44.40 | 1.98 | 19.69 | 3.26 | 0.6265 | 0.6265 | 8.54 | 14.02 | 0.383 | 1.67 | 7.56 | -- | 2.92 | 1.42 | 3.27 | 1.62 | 68.90 | 69.18 | 7.62 | 3.96 | 1.22 | 7.96 | 0.2519 | 0.00 | 13.42 | 42.94 | 74.59 | -9.36 | 21.97 | -- |
| Pharma Mar SA | 179.28m | 34.01m | 1.38bn | 500.00 | 39.73 | 6.83 | 32.85 | 7.71 | 1.93 | 1.93 | 10.21 | 11.24 | 0.5314 | 0.1946 | 5.34 | 358,552.00 | 10.08 | 18.37 | 13.70 | 25.03 | 94.53 | 94.02 | 18.97 | 29.81 | 2.14 | -- | 0.2031 | -- | 10.56 | 15.30 | 2,197.71 | -- | 31.72 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 162.08m | 29.44m | 1.39bn | 1.52k | 46.91 | 3.97 | -- | 8.55 | 1.37 | 1.37 | 7.55 | 16.23 | 0.3809 | 1.83 | 5.89 | 873,161.50 | 6.92 | 8.09 | 8.44 | 9.82 | 71.90 | 81.72 | 18.16 | 20.10 | 3.12 | -- | 0.0444 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
| Alembic Pharmaceuticals Ltd | 676.14m | 58.52m | 1.41bn | 16.57k | 24.01 | -- | 16.36 | 2.08 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
Data as of Feb 13 2026. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR
6.58%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 473.29k | 2.63% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 205.17k | 1.14% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 117.25k | 0.65% |
| �KOWORLD LUX SAas of 30 Jun 2025 | 102.00k | 0.57% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 65.46k | 0.36% |
| Jupiter Asset Management Ltd.as of 31 Oct 2025 | 61.13k | 0.34% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 60.38k | 0.34% |
| Caixabank Asset Management SGIIC SAas of 31 Dec 2025 | 39.80k | 0.22% |
| DWS Investments (UK) Ltd.as of 05 Feb 2026 | 34.53k | 0.19% |
| BNP Paribas Asset Management Europe SASas of 02 Feb 2026 | 26.11k | 0.15% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
